Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Pumpers don't get holidays....so expect Clown here all summe
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon May 31, 2022 11:46pm
129 Views
Post# 34722146

RE:RE:RE:RE:Pumpers don't get holidays....so expect Clown here all summe

RE:RE:RE:RE:Pumpers don't get holidays....so expect Clown here all summe
nobeard wrote: Seems like Chinachin, stutters and stockings are all the same person verbally attacking one person. I don't know what it takes for the moderators to put this person in the penalty box. Ate question to ponder:. If long term pain medication is being resolved would not the royality payments be back on the table with the Chinese company?
Mmmtroll wrote:
these trolls aren't even entertaining. It's sorta sad they like mugsy groupies lol


Good question nobeard.
I think it came up at Bloom Burton during Q&A.
If I understood Dan's response, he clarified that the Nuance (China) deal was related to all things  OTENA.

Therefore, Nuance would be looking at acute, chronic and any other indications that come up specifically for OTENA.

I will try to confirm that.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities